or Try an Advanced Search...

    Adoptive Cell Transfer Stocks List

    Symbol Grade Name % Change
    CERO C CERo Therapeutics Holdings, Inc. 10.41
    CLLS D Cellectis S.A. -2.95
    IOVA F Iovance Biotherapeutics, Inc. 2.40
    ADAP F Adaptimmune Therapeutics plc -3.72
    IMTX F Immatics N.V. -0.29
    ALLO F Allogene Therapeutics, Inc. 0.49
    ACET F Adicet Bio, Inc. -2.11
    View As Page of Charts
    Related Industries: Biotechnology Other
    Related Stock Lists: Cancer Medicine Biopharmaceutical Cancer Immunotherapy Cell Therapy Clinical Medicine Immune System Immunotherapy Solid Tumors Biotechnology Cancer Treatment Tumors Of The Hematopoietic And Lymphoid Tissues Virotherapy Breast And Lung Cancer Cancer Immunotherapy Product Chimeric Antigen Receptor Hematological Malignancies Immunotherapy Products Melanoma Multiple Myeloma

    Related ETFs - A few ETFs which own one or more of the above listed Adoptive Cell Transfer stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 4.38
    WDNA D WisdomTree BioRevolution Fund 2.58
    IDNA D iShares Genomics Immunology and Healthcare ETF 2.38
    BBP C BioShares Biotechnology Products Fund 1.48
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 1.32
    View all Adoptive Cell Transfer ETFs...
    Compare ETFs
    Compare BBP to BBC Compare IDNA to BBC Compare WDNA to BBP

        Adoptive Cell Transfer Stocks Recent News

        Date Stock Title
        Nov 20 IMTX Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Nov 19 ALLO Allogene Therapeutics Announces Participation in December Investor Conferences
        Nov 19 IMTX Immatics Sees Revenue Surge Despite R&D Expenses
        Nov 18 ACET Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
        Nov 18 ALLO Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
        Nov 18 IMTX Immatics GAAP EPS of -€0.11, revenue of €50.56M
        Nov 18 IMTX Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
        Nov 18 ACET Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
        Nov 18 ACET Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
        Nov 16 ACET Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
        Nov 16 ADAP Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 15 CERO CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
        Nov 15 ADAP Halozyme bids for Evotec; BeiGene gets a new name
        Nov 14 ADAP Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
        Related Industries: Biotechnology Other
        Related Stock Lists: Cancer Medicine Biopharmaceutical Cancer Immunotherapy Cell Therapy Clinical Medicine Immune System Immunotherapy Solid Tumors Biotechnology Cancer Treatment Tumors Of The Hematopoietic And Lymphoid Tissues Virotherapy Breast And Lung Cancer Cancer Immunotherapy Product Chimeric Antigen Receptor Hematological Malignancies Immunotherapy Products Melanoma Multiple Myeloma
        Adoptive Cell Transfer

        Adoptive cell transfer (ACT) is a type of immunotherapy that involves taking immune cells from a patient, modifying them in the laboratory, and then infusing them back into the patient to help fight cancer. ACT works by boosting the patient’s own immune system to recognize and attack cancer cells. It is used to treat a variety of cancers, including melanoma, lymphoma, and leukemia.

        Browse All Tags